查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球生物可吸收血管支架市场 -2023-2030
市场调查报告书
商品编码
1374800

全球生物可吸收血管支架市场 -2023-2030

Global Bioresorbable Vascular Scaffolds Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

生物可吸收血管支架是一种新型支架，用于疏通阻塞的动脉。该支架可作为阻塞动脉中的临时支架，并随着癒合完成而慢慢溶解。这样，患者体内就不会残留任何残留物。

生物可吸收支架可能比其他技术具有潜在优势。与传统支架相比，它们具有卓越的适形性和灵活性，可减少组织生物力学分布的变化并保留血管几何形状。 「将血管从金属笼中解放出来」可以帮助恢復生理血管运动、机械传导、适应性剪切应力、晚期管腔增益（与永久性支架的晚期管腔损失相反）和晚期扩张重塑。

或许，生物可吸收血管支架最显着的优点是它们在病人体内的存在只是暂时的。它们在三年内溶解并帮助容器恢復其自然状态。因此，生物可吸收血管支架对于适合这些装置的患者来说是一个很好的选择。

市场动态：驱动因素与限制因素

冠状动脉疾病盛行率上升

生物可吸收血管支架已成为治疗冠状动脉疾病（CAD）的传统金属支架的有前途的替代品。随着越来越多的患者寻求 CAD 治疗，医疗保健提供者正在寻求创新的解决方案，以提供更好的结果，同时最大限度地减少与传统治疗相关的风险和併发症。由于技术的进步，BVS 的设计和製造流程变得比以往更加可靠和有效。

冠状动脉疾病是由向心臟供血的动脉（称为冠状动脉）壁上斑块积聚引起的。斑块由胆固醇沉淀物组成。随着时间的推移，斑块的堆积会导致动脉内部变窄。这个过程称为动脉粥状硬化

例如，根据美国疾病管制与预防中心2023 年更新情况说明书，冠状动脉心臟病是最常见的心臟病类型，2021 年将导致375,476 人死亡。20 岁及以上的成年人中约有二分之一患有CAD （约5%） .2 到 2021 年，大约十分之二的 CAD 死亡病例发生在 65 岁以下的成年人中。

此外，全球生物可吸收血管支架市场受到各种其他因素的推动，例如新技术进步、微创手术采用的增加、新兴市场新产品的推出、老年人口的增加、监管批准的增加这将在预测期内进一步推动市场。

市场动态：克制

有限的临床证据生物可吸收支架市场面临长期临床证据有限的挑战。与传统支架相比，生物可吸收支架植入物的结果需要进一步评估，以最终确定其有效性和安全性。另一个问题是製造流程复杂，生物可吸收支架复杂的製造流程导致其成本较高。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按设备类型分類的片段
  • 按应用程式片段
  • 按材料类型分類的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 冠状动脉疾病盛行率上升
      • 科技进步的崛起
    • 限制
      • 临床证据有限
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按装置类型

  • 依维莫司洗脱装置
  • 诺维莫司洗脱装置
  • 西罗莫司洗脱装置

第 8 章：按应用

  • 冠状动脉疾病
  • 週边动脉疾病

第 9 章：依材料类型

  • 聚左旋乳酸 (PLLA)
  • 酪胺酸衍生聚碳酸酯
  • 其他的

第 10 章：最终用户

  • 医院
  • 门诊手术中心 (ASC)
  • 心导管实验室
  • 其他的

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

    • 百多力
    • 公司简介
    • 产品类型组合和描述
    • 财务概览
    • 主要进展
  • 瑞瓦医疗
  • 动脉
  • 梅里尔生命科学列兵。有限公司
  • 卓瑞安医疗
  • 透光灯
  • 雅培
  • 波士顿科学公司
  • 奈米疗法
  • 纲医学

第 14 章：附录

简介目录
Product Code: MD7218

Overview

A bioresorbable vascular scaffold is a newer type of stent used to open up a blocked artery. This stent acts as a temporary scaffold in a blocked artery and slowly dissolves over time as healing completes. This way, no residue gets left in the patient's body.

Bioresorbable scaffolds may offer potential advantages over other technologies. Their superior conformability and flexibility compared with conventional stents reduce altered distribution of the tissue biomechanics and preserve vessel geometry. The 'liberation of the vessel from a metallic cage' can help in the restoration of physiological vasomotion, mechanotransduction, adaptive shear stress, late luminal gain (as opposed to late luminal loss with permanent stents), and late expansive remodelling.

Perhaps, the most significant advantage of bioresorbable vascular scaffolds is that their presence in the patient's body is only temporary. They dissolve over three years and help the vessel return to its natural state. Thus, bioresorbable vascular scaffolds are an excellent option for patients deemed fit for these devices.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of coronary artery diseases

Bioresorbable vascular scaffolds have emerged as a promising alternative to traditional metallic stents in the treatment of coronary artery disease (CAD). As more patients seek treatment for CAD, healthcare providers look for innovative solutions that can provide better outcomes while minimizing risks and complications associated with traditional treatments. BVS design and manufacturing processes are becoming more reliable and effective than ever before due to advancements in technology.

Coronary artery disease is caused by plaque buildup in the wall of the arteries that supply blood to the heart (called coronary arteries). Plaque is made up of cholesterol deposits. Plaque buildup causes the inside of the arteries to narrow over time. This process is called atherosclerosis

For instance, according to the Centers for Disease Control and Prevention updated factsheet 2023, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021. About 1 in 20 adults age 20 and older have CAD (about 5%).2 In 2021, about 2 in 10 deaths from CAD happen in adults less than 65 years old.

Furthermore, the global bioresorbable vascular scaffolds market is driven by various other factors like new technological advancements, a rise in the adoption of minimally invasive procedures, the launch of novel products in emerging markets, a rise in the geriatric population, an increase in regulatory approvals that will further drive the market during the forecast period.

Market Dynamics: Restraint

Limited clinical evidence the bioresorbable scaffolds market faces a challenge in terms of limited long-term clinical evidence. The outcomes of bioresorbable scaffold implants compared to traditional stents need further evaluation to establish their efficacy and safety conclusively. Another issue is the complex manufacturing process, the intricate manufacturing process of bioresorbable scaffolds contributes to their higher costs.

Segment Analysis

The global bioresorbable vascular scaffolds is segmented based on device type, application, material type, end user and region.

The everolimus-eluting device from the device type segment accounted for approximately 41.2% of the market share

The everolimus-eluting device from the device type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Everolimus-eluting device refers to a medical device that releases everolimus, a drug that inhibits cell proliferation and reduces the risk of restenosis, into the coronary artery wall to prevent re-narrowing of the blood vessel caused by coronary artery disease.

For instance, in June 2022, Shanghai MicroPort Medical (Group) Co., Ltd released the 2-year clinical follow-up results from the pivotal FUTURE II trial of its self-developed, second-generation, fully bioresorbable vascular scaffolds system - Firesorb Bioresorbable Rapamycin Targeted Eluting Coronary Scaffold System.

The FUTURE II trial is a prospective, multi-centre, non-inferiority designed randomized controlled trial comparing the safety and efficacy of the second-generation thinner-strut bioresorbable eluting scaffolds - Firesorb and that of a market-leading everolimus-eluting metallic stent. The FUTURE II trial was conducted at 28 medical centres in China and enrolled a total of 433 patients with obstructive coronary atherosclerotic heart disease.

Moreover, in September 2020 Abbott stated that it started the LIFE-BTK clinical trial for its Espirit BTK everolimus-eluting resorbable scaffold system. According to a news release, Abbott's Espirit system is the first to begin an investigational device exemption (IDE) trial in the U.S. for a fully resorbable device for treating below-the-knee blocked arteries or critical limb ischemia (CLI) in people battling advanced stages of peripheral artery disease (PAD).

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the sophisticated healthcare infrastructure, rise in patient awareness about minimally invasive treatments, and high disposable income rising disease burden and changing lifestyle of people. Additionally, the strong foothold of industry players in the region will provide innovative solutions that will increase the adoption rate and are anticipated to drive the bioresorbable vascular scaffold industry in North America.

For instance, in September 2022 REVA Medical, LLC, a leader in bioresorbable polymer technologies for vascular applications, stated that enrollment in the MOTIV pivotal trial has been initiated at clinical centres in both the U.S. and Europe. The study will evaluate the use of the MOTIV Sirolimus-Eluting Bioresorbable Vascular Scaffold for treatment in patients suffering from chronic limb-threatening ischemia (CLTI).

COVID-19 Impact Analysis

During this pandemic of COVID-19, the rising prevalence of cardiovascular diseases and accompanying surgery adoptions is accelerating market growth. Amid this pandemic, the demand for bioresorbable scaffolds is increasing as they provide complete resorption and temporal mechanical support for patients.

Bioresorbable scaffolds are widely used as potential solutions for coronary artery diseases. These scaffolds prevent the adverse reactions caused by permanent metallic devices during percutaneous coronary intervention, which is a safe, effective, and timely preferred treatment for coronary artery diseases.

Competitive Landscape

The major global players in the Bioresorbable Vascular Scaffolds market include: BIOTRONIK, REVA Medical, Arterius, Meril Life Sciences Pvt. Ltd, Zorion Medical, Translumina, Abbott, Boston Scientific Corporation, Nano Therapeutics, Tsuna Med and among others.

Key Developments

  • In March 2021, Meril Life Sciences stated that it has launched indigenously researched and developed bioresorbable scaffold (BRS) MeRes100. Bioresorbable scaffolds are non-metallic, non-permanent mesh tubes, similar to stents, that dissolve over time after ensuring the previously blocked artery is opened via a routine angioplasty procedure.

Why Purchase the Report?

  • To visualize the global bioresorbable vascular scaffolds market segmentation-based device type, application, material type, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of bioresorbable vascular scaffolds market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global bioresorbable vascular scaffolds market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Material Type
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the prevalence of coronary artery diseases
      • 4.1.1.2. Rise in the technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Limited clinical evidence
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Everolimus-eluting Device*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Novolimus-eluting Device
  • 7.4. Sirolimus-eluting Device

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Coronary Artery Disease*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Peripheral Artery Disease

9. By Material Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.1.2. Market Attractiveness Index, By Material Type
  • 9.2. Poly-L-Lactic Acid (PLLA)*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Tyrosine-derived Polycarbonate
  • 9.4. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Ambulatory Surgical Centers (ASCs)
  • 10.4. Cardiac Catheterization Labs
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

    • 13.1.1. BIOTRONIK
    • 13.1.2. Company Overview
    • 13.1.3. Product Type Portfolio and Description
    • 13.1.4. Financial Overview
    • 13.1.5. Key Developments
  • 13.2. REVA Medical
  • 13.3. Arterius
  • 13.4. Meril Life Sciences Pvt. Ltd.
  • 13.5. Zorion Medical
  • 13.6. Translumina
  • 13.7. Abbott
  • 13.8. Boston Scientific Corporation
  • 13.9. Nano Therapeutics
  • 13.10. Tsuna Med

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us